Angiotech acquires manufacturing and intellectual property rights to develop human biological adhesives, hemostats and therapeutic proteins VANCOUVER, April 7 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc.

MONTREAL, April 7 /PRNewswire/ - Haemacure Corporation announces the closing of the purchase by Angiotech Pharmaceuticals, Inc. of substantially all its assets, consisting mainly of its two product candidates and the associated intellectual property and manufacturing plant.

TSX:HAE MONTREAL, March 22 /PRNewswire/ - Haemacure Corporation (TSX:HAE) announces that it has obtained authorization from the Superior Court of the Province of Quebec to sell its assets to Angiotech Pharmaceuticals, Inc., a secured creditor of Haemacure.

TSX:HAE MONTREAL, Feb.

HAE:TSX MONTREAL, Jan.